IDEAYA Biosciences Inc., a precision medicine oncology company, has announced that data from its Phase 2 clinical trial of neoadjuvant darovasertib in primary uveal melanoma will be presented at the 2025 European Society of Medical Oncology (ESMO) meeting, scheduled for October 17-21 in Berlin, Germany. The presentation will cover preliminary results from over 90 patients across both plaque brachytherapy and enucleation-eligible cohorts. Darovasertib has received U.S. FDA Breakthrough Therapy Designation for this indication, and the company has commenced a global Phase 3 neoadjuvant registrational trial in primary uveal melanoma, known as OptimUM-10, in the third quarter of 2025. Dr. Marcus Butler from the Princess Margaret Cancer Center at the University of Toronto will present the findings. Further details from the abstract will be disclosed at a later date.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。